Skip to main content Back to Top
Advertisement

5/9/2019

Doxycycline Hyclate Injection

Products Affected - Description

    • Doxycycline hyclate lyophilized powder for injection, Mylan Institutional, 100 mg, vial, 10 count, NDC 67457-0437-10
    • Doxycycline hyclate lyophilized powder for injection, Zydus, 100 mg, vial, 10 count, NDC 68382-0910-10

Reason for the Shortage

    • Mylan Institutional did not provide a reason for the shortage.
    • Zydus did not provide a reason for the shortage.

Available Products

    • Doxycycline hyclate lyophilized powder for injection, Fresenius Kabi, 100 mg, vial, 10 count, NDC 63323-0130-11

Estimated Resupply Dates

    • Mylan Institutional has doxycycline 100 mg vials on back order and the company estimates a release date of mid- to late-June 2019.
    • Zydus has doxycycline 100 mg vials on allocation.

Updated

Updated May 9, 2019 by Stephen Andrews, PharmD, Drug Information Specialist. Created May 1, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins